New Molecular Insights into the Genetics of Thrombophilia. Resistance to Activated Protein C Caused by Arg⁵⁰⁶ to Gin Mutation in Factor V as a Pathogenic Risk Factor for Venous Thrombosis

• References

• 1 Goldhaber SZ. TEpidemiology of pulmonary embolism and deep vein thrombosis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenhamn EG D. eds. Haemostasis and Thrombosis. 3rd. ed. Churchill Livinstone: 1994: 1327-1333
• 2 Thomas DP. TPathogenesis of venous thrombosis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG D. eds. Haemostasis and Thrombosis. 3rd. ed. Churchill Livingstone: 1994: 1335-1347
• 3 Allaart CF, Briët E. Familial venous thrombophilia. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG D. eds. Haemostasis and Thrombosis. 3rd. ed. Churchill Livingstone: 1994: 1349-1360
• 4 Dahlbä ck, Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease -critical evaluation of laboratory investigation. Thromb Haemost 1992; 68: 7-13
• 5 Heijboer H, Brandjes D, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516
• 6 Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposion to thrombosis. Cell 1993; 72: 477-480
• 7 Tabemero MD, Tomas IF, Alberca I, Orfao A, Borrasca AL, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-254
• 8 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
• 9 Bertina RM, Koeleman BP C, Koster T, Rosendaal FR, Dirven RH, de Reside H, vanderVelden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 10 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1362-1363
• 11 Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538
• 12 Voorberg J, Roelse J, Koopman R, Büller H, Berends F, ten Cate JT, Mertens K, vanMourik JA. Association of idiopathicthromboembolism with single point mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536
• 13 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-521
• 14 Koster T, Rosendaal FR, de Ronde F, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506
• 15 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintainance, and regulation. Biochemistry 1991; 30: 10363-10370
• 16 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8
• 17 Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-518
• 18 Kane WH, Davie EW. Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and trombotic disorders. Blood 1988; 71: 539-555
• 19 Jenny RJ, Tracy PB, Mann KG. The physiology and Biochemistry of factor V. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG D. eds. Haemostasis and Thrombosis. 3rd. ed. Churchill Livingstone: 1994: 465-476
• 20 Esmon CT. Molecular events that control the protein C anticoagulant pathway. Thromb Haemost 1993; 70: 29-35
• 21 Esmon CT. Cell mediated events that control blood coagulation and vascular injury. Annu Rev Cell Biol 1993; 9: 1-26
• 22 Dahlbäck B. Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991; 66: 49-61
• 23 Esmon CT. The Protein C Anticoagulant Pathway. Arterioscler Thromb 1992; 12: 135-145
• 24 Dahlbäck B, Stenflo J. The protein C anticoagulant system. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H. eds. The molecular basis of blood diseases. Philadelphia: W: Saunders B. 1994: 599-628
• 25 Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C system. FASEB J 1992; 6: 2561-2567
• 26 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem 1994; 269: 18735-18738
• 27 Marlar RA, Kressin DC, Madden RM. Contribution of plasma proteinase inhibitors to the regulation of activated protein C in plasma. Thromb Haemost 1993; 69: 16-20
• 28 Fay PJ. Factor VIII structure and function. Thromb Haemost 1993; 70: 63-67
• 29 Kalifatis M, Mann KG. Role of the membrane in the inactivation of factor Va by activated protein C. J Biol Chem 1993; 268: 27246-27257
• 30 Odegaard B, Mann KG. Proteolysis of factor Vaby factor Xa and activated protein C. J Biol Chem 1987; 262: 11233-11238
• 31 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation ofhuman factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880
• 32 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-4746
• 33 Stenflo J. A new vitamin K-dependent protein. J Biol Chem 1976; 251: 355-363
• 34 Kisiel W, Canfield WM, Ericsson LH, Davie EW. `Anticoagulant properties of bovine plasma protein C following activation by thrombin. J Biol Chem 1977; 16: 5824-5831
• 35 He X, Shen L, Bjartell A, Malm J, Lilja H, Dahlbäck B. The gene encoding vitamin K-dependent anticoagulant protein C is expressed in human male reproductive tissues. J Histochem Cytochem. 1995 (in press)
• 36 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249-2252
• 37 Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor forthrombin-catalyzed activation of protein C. J Biol Chem 1982; 257: 859-864
• 38 Walker FJ. Regulation of activated protein Cby a new protein. J Biol Chem 1980; 255: 5521-5524
• 39 Walker FJ. Regulation of activated protein C by protein S, the role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256: 11128-11131
• 40 Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-2877
• 41 Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Nad Acad Sci USA 1994; 91: 2728-2732
• 42 Hackeng TM, van’t Veer C, Meijers JC M, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions withfactors Va and Xa. J Biol Chem 1994; 269: 21051-21058
• 43 Dahlbäck B, Lundwall Å, Stenflo J. Primary structure of bovine vitamin Independent protein S. Proc Natl Acad Sci USA.
• 44 Discipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX, factor X, and protein S. Biochemisty 1977; 16: 698-706
• 45 Dahlbäck B, Stenflo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sci USA 1981; 78: 2512-2516
• 46 Dahlbäck B. Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. Biochem J 1983; 209: 837-846
• 47 Dahlbäck B. Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. Biochem J 1983; 209: 847-856
• 48 Dahlbäck B. Inhibition of protein C_a cofactor function ofhuman and bovine protein S by C4b-binding protein. J Biol Chem 1986; 261: 12022-12027
• 49 Beitina RM, van Wijngaarden A, Reinalda-Poot J, Poort SR, Bom VJ. Determination of plasma protein S - the protein cofactor of activated protein C. Thromb Haemost 1985; 53: 268-272
• 50 Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-2088
• 51 Suzuki K, Nishioka J, Matsuda J, Maruyama I, Hashimoto S. Protein S is essential for the activated protein C-catalyzed inactivation of platelet-associated factor Va. J Biochem 1984; 96: 455-460
• 52 Harris KW, Esmon CT. Protein S is required for bovine platelets to support activated protein C binding and activity. J Biol Chem 1985; 260: 2007-2010
• 53 Stem DM, Nawroth PP, Harris KW, Esmon CT. Cultured bovine aortic endothelial cells promote activated protein C - protein S-mediated inactivation of factor Va. J Biol Chem 1986; 261: 713-718
• 54 Nelsestuen GL, Kisiel W, Discipio RG. Interaction of vitamin K dependent proteins with membranes. Biochemistry 1978; 17: 2134-2138
• 55 Dahlbäck B, Wiedmer T, Sims PJ. Binding of anticoagulant vitamin K-dependent protein S to platelet-derived microparticles. Biochemisty 1992; 31: 12769-12777
• 56 Bakker H, Tans G, Janssen-Claessen T, Thomassen MC L G D, Hemker HC, Griffin JH, Rosing J. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem 1992; 208: 171-178
• 57 Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membrane-bound factor V by activated protein C. J Biol Chem 1988; 263: 14884-14890
• 58 Regan LM, Lamphear BJ, Walker FJ, Fay PJ. Factor IXa protects factor Villa from activated protein C: Factor IXa inhibits activated protein C- catalyzed cleavage of factor VIIIa at Arg⁵⁶² . J Biol Chem 1994; 269: 9445-9452
• 59 Salem HH, Esmon NL, Esmon CT, Majerus PW. Effects ofthrombomodulin and coagulation factor Va-light chain on protein C activation in vitro. J Clin Invest 1984; 73: 968-972
• 60 Gladson CL, Scharrer I, Hach V, Beck KH, Griffin JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22
• 61 Reitsma PH, Poort SR, Bemardi F, Gandrille S, Long GL, Sala N, Cooper DN. Protein C deficiency: a database of mutations. Thromb Haemost 1993; 69: 77-84
• 62 Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990; 16: 299-309
• 63 Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, Tchemia G. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with purified protein C concentrate. N Engl J Med 1991; 325: 1565-1568
• 64 Bovill EG, Bauer KA, Dickermann JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73: 712-717
• 65 Allaart CF, Pooit SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased risk of venous thrombosis in carriers of hereditaiy protein C deficiency defect. Lancet 1993; 341: 134-138
• 66 Reitsma PH, Pooit SR, Allaait CF, Briët E, Bertina RM. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: Heterogeneity and founder effects. Blood 1991; 78: 890-894
• 67 Miletich JP, Sherman L, Broze Jr GJ. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996
• 68 Seligsohn U, Berger A, Abend A, Rubin L, Attias D, Zivelin A, Rapaport SI. Homozygous protein C deficiency manifested by massive thrombosis in the newborn. N Engl J Med 1984; 310: 559-562
• 69 Koeleman BP C, Reitsma PH, Allaart CF, Beitina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035
• 70 Engesser L, Broekmans AW, Briët E, Brommer EJ P, Bertina RM. Hereditaiy protein S deficiency: Clinical manifestations. Ann Intern Med 1987; 106: 677-682
• 71 Mannucci PM, Tripodi A, Bertina RM. Protein S deficiency associated with “juvenile” arterial and venous thrombosis. Thromb Haemost 1986; 55: 440-440
• 72 Allaait CF, Aronson DC, Ruys T, Rosendaal FR, van Bockel JH, Bertina RM, Briët E. Hereditary protein S deficiency in young adults with arterial occlusive disease. Thromb Haemost 1990; 64: 206-210
• 73 Reitsma PH, Ploos van Amstel HK, Bertina RM. Three novel mutations in five unrelated subjects with hereditary protein S deficiency type I. J Clin Invest 1994; 93: 486-492
• 74 Gandrille S, Brogel D, Eschwege-Gufflet V, Aillurd MF, Dreyfus M, Matheron C, Gaussem P, Abgrall JF, Jude B, Sié P, Toulon P, and Aiach M. Identification of 15 different candidate causal point mutations and 3 polymoiphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood 1995; 85: 130-138
• 75 Schmidel DK, Nelson RM, Broxson EH, Comp PC, Marlar RA, Long GL. A 5.3-kb deletion including exon XIII of the protein S a gene occurs in two protein S-deficient families. Blood 1991; 77: 551-559
• 76 Ploos van Amstel HK, Huisman MV, Reitsma PH, ten Cate JW, Bertina RM. Partial protein S gene deletion in a family with hereditaiy thrombophilia. Blood 1989; 73: 479-483
• 77 Bertina RM, Ploos van Amstel HK, van Wijngaarden A, Coenen J, Leemhuis MP, Deutz-Terlouw PP, Van Der Linden IK, Reitsma PH. Heerlen polymoiphism of the protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood 1990; 76: 538-548
• 78 Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986; 67: 504-508
• 79 Comp PC, Esmon CT. Recurrent thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-1528
• 80 Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin IH. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-1300
• 81 Zöller B, Garcia de Frutos P, Dahlbäck B. Evaluation of the relationship between protein S and C4b-binding protein isofoims in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genotype. Blood. 1994 submitted:
• 82 Mannucci PM, Valsecchi C, Krashmalnicoff A, Faioni EM, Tripodi A. Familial dysfunction of protein S. Thromb Haemost 1989; 62: 763-766
• 83 Hayashi T, Nishioka J, Shigekiyo T, Saito S, Suzuki K. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S. Blood 1994; 83: 683-690
• 84 Faioni EM, Franchi F, Asti D, Sacchi E, Bemardi F, Mannucci PM. Resi stance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-1071
• 85 Dahlbäck B. Thrombophilia. In: Friedmann T, Gianelli FG. eds. Advances in Genetics. Orlando,FL: Academic Press; 1995. in press
• 86 Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Nad Acad Sci USA 1994; 81: 1396-1400
• 87 Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 3120-3125
• 88 Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston E, Peake IR. High prevalence of a mutation in the factor V gene within the UK population: Relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-222
• 89 Baker R, Thom J, Vanbockxmeer F. Diagnosis of activated protein C resistance (factor V Leiden). Lancet 1994; 344: 1162-1162
• 90 Alhenc-Gelas M, Gandrille S, Aubry ML, Emmerich J, Fiessinger JN, Aiach M. Unexplained thrombosis and factor V Leiden mutation. Lancet 1994; 344: 555-556
• 91 Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1994 submitted:
• 92 Svensson PJ, Dahlbäck B. Novel mechanism for thrombosis characterized by poor anticoagulant response to activated protein C constitutes a major cause of thrombophilia. Thromb Haemost 1993; 69: 999-999
• 93 Svensson PJ, Dahlbäck B. Twenty novel families with thrombophilia and inherited resistance to activated protein C. Thromb Haemost 1993; 69: 1252 (abstract)
• 94 Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-1993
• 95 Halbmayer WM, Haushofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinol 1994; 5: 51-57
• 96 Lindblad B, Svensson PJ, Dahlback B. Arterial and venous thromboembolism with fatal outcome in a young man with inherited resistance to activated protein C. Lancet 1994; 343: 917-917
• 97 Holm J, Zöller B, Svensson PJ, Bemtorp E, Erhardt L, Dahlbäck B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344: 952-953
• 98 Cushman M, Bhushan F, Bovill E, Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost 1994; 72: 647-647
• 99 Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of premature myocardial infarction. Lancet 1994; 344: 1709-1710
• 100 Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524
• 101 Dahlbäck B. Physiological anticoagulation. Inherited resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-927
• 102 Zöller B, Bemtsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 1994 in press
• 103 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral -contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457
• 104 Majerus PW. Bad blood by mutation. Nature 1994; 369: 14-15
• 105 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-886
• 106 Rosén S, Johansson K, Lindberg K, Dahlbäck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 1994; 72: 255-260
• 107 Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163
• 108 Trossaert M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709-1709
• 109 Cripe LD, Moore KD, Kane WH. Structure of the geneforhuman coagulation factor V. Biochemistry 1992; 31: 3777-3785
• 110 Bauer KA. Hypercoagulability - a new cofactor in the protein C anticoagulant pathway. N Engl J Med 1994; 330: 566-567
• 111 Dahlbäck B. Bovine coagulation factor V visualized with electron microscopy; ultra structure of the isolated activated forms and of the activation fragments. J Biol Chem 1986; 261: 9495-9501
• 112 Dahlbäck B. Inherited thrombophilia. Resistance to activated protein C as a basis for venous thromboembolism. Blood 1995; 85: 607-614